Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts
| Autor: | Clara Natoli, Albana Cumashi, Rossano Lattanzio, Nicola Tinari, Stefano Iacobelli, Mauro Piantelli, Cosmo Rossi |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
Cancer Research Indoles Administration Oral Mice Nude Angiogenesis Inhibitors Docetaxel Pharmacology urologic and male genital diseases Drug Administration Schedule Prostate cancer Mice Cell Line Tumor Antineoplastic Combined Chemotherapy Protocols medicine Sunitinib Initial treatment Animals Humans Pyrroles Dosing Infusions Intravenous neoplasms Cell Proliferation Dose-Response Relationship Drug business.industry organic chemicals Low dose Prostatic Neoplasms Sunitinib malate medicine.disease Xenograft Model Antitumor Assays female genital diseases and pregnancy complications Oncology Tolerability Taxoids business therapeutics medicine.drug |
| Zdroj: | Cancer letters. 270(2) |
| ISSN: | 1872-7980 |
| Popis: | The aim of the study was to evaluate the activity of the antiangiogenic agent SU-11248 (sunitinib malate, Sutent®), alone or in combination with docetaxel. To this end, animals bearing DU-145 human hormone-refractory prostate cancer (HRPC) xenografts were treated with sunitinib (40 mg/kg daily, p.o.), docetaxel (10 or 30 mg/kg/week, i.v.), a combination of sunitinib (40 mg/kg daily) and docetaxel (10 mg/kg/week) or vehicle alone. At the end of the 3-week dosing schedule, single-agent treatment induced a tumor regression of 59%, 49% and 75% for sunitinib, docetaxel 10 mg/kg, and docetaxel 30 mg/kg, respectively. The combination of sunitinib with low-dose (10 mg/kg) docetaxel produced a tumor regression comparable to that obtained with high-dose (30 mg/kg) docetaxel, but tolerability was higher as indicated by mice weight. Both sunitinib and docetaxel inhibited tumor regrowth after initial treatment with the alternate drug. These results suggest that sunitinib alone or in combination with low-dose docetaxel may have a role in the treatment of HRPC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect